Shandong Weigao Group Medical Polymer Co. Ltd. Class H · HKEX:1066
Shandong Weigao Group Medical Polymer Co. Ltd. Class H — H1 2025 Earnings Presentation
21 slides from Shandong Weigao Group Medical Polymer Co. Ltd. Class H's earnings presentation, Aug 27, 2025
Slide 1: 2025 Interim Results
2025 Interim Results August 27, 2025
Slide 2: Contents
CONTENTS I. Strategy and business development II. Key financials
Slide 3: Strategy and business development
01 PART ONE Strategy and business development P A R T
Slide 4: China's leading integrated healthcare solution provider
China’s leading integrated healthcare solution provider Build a leading medical device company distinguished by superior quality and cost efficiency, a comprehensive sales network and a diversified product portfolio under three key business strategies Platformization - Leverage the advantages of an
Slide 5: Results overview
Results overview 01 Stable margin revenue and slightly decreased net profit Accelerated expansion into new fields with robust pipeline 03 • During the period, revenue reached RMB6.64bn, • In H1, R&D expenses reached RMB320m, accounting remaining flat YoY; sales expense ratio down by 0.7%, for 4.7% o
Slide 6: Business segments and major products
Business segments and major products Blood management Blood bags, X-ray irradiation system Interventional products Biopsy needle, etc. 6.8% Thrombectomy System 14.9% 49.7% General medical device Orthopaedics 11.0% (general consumables) Spine Infusion set and other general Joint, sports medicine cons
Slide 7: General medical device: stable pricing with modest sales growth
General medical device: stable pricing with modest sales growth ❖ In H1, segment revenue was RMB3.30bn, remaining flat YoY; segment profit was RMB490m, down by 17.1% YoY ❖ Infusion sets, indwelling venous catheters, syringes and other major products remained stable in price with single-digit growth
Slide 8: General medical device: deepen strategic layout for specialty consumables
General medical device: deepen strategic layout for specialty consumables driven by consumables and devices Focusing on general consumable upgrade and specialty consumable expansion, Company has built a new product pipeline centered on mid-to-high-end consumables and supported by complementary equip
Slide 9: Pharma packaging: resilient domestic market and accelerated international expansion
Pharma packaging: resilient domestic market and accelerated international expansion driven by strategic partnership 上半年业绩亮点 ❖ Segment revenue was RMB1.17bn, remaining flat YoY; segment profit was RMB450m, down by 5.8% YoY ❖ The domestic unit price of pre-fillable syringe remained stable, with a sing
Slide 10: Orthopaedics: double-digit growth achieved in spine business
Orthopaedics: double-digit growth achieved in spine business; joint business expected to accelerate in H2 ❖ Segment revenue was RMB730m, slightly down by 1.6% YoY; segment profit was RMB150m, significantly up by 74.3% YoY ❖ Spine business achieved double-digit sales growth both year-on-year and quar
Slide 11: Orthopaedics: advance innovation with a focus on minimally invasive spine solutions
Orthopaedics: advance innovation with a focus on minimally invasive spine solutions and pain management Expand into areas such as new material, regenerative rehabilitation, intelligent assistance and 3D printing, with a strategic focus on minimally invasive spine solutions and pain management Orthop
Slide 12: Interventional products: stable overseas market with thrombectomy system scale-up
Interventional products: stable overseas market with the scale-up of thrombectomy system accelerated ❖ Segment revenue was RMB990m, down by 2% YoY. Performance across the U.S., Europe, Middle East, and Africa regions showed a single-digit growth YoY ❖ Sales of interventional biopsy reached single-di
Slide 13: Blood management: gradual recovery in demand with overseas expansion
Blood management: gradual recovery in demand with sustained overseas expansion anticipated ❖ Segment revenue was RMB450m, up by 8.1% YoY, primarily driven by the recovery in overseas procurement demand; segment profit was RMB31m, down by 5.3% YoY ❖ Overseas sales for blood bags and other transfusion
Slide 14: Medium to long term outlook
Medium to long term outlook Seize import substitution opportunities driven by volume- based procurement and rapidly expand product portfolio to meet deeper demand across broad coverage area Expand lean manufacturing capabilities into high-demand specialty consumables and ancillary equipment 1 Transi
Slide 15: Key financials
02 PART TWO Key financials P A R T
Slide 16: Key financials
Key financials Revenue (RMBm) Overseas sales (RMBm) 6,898 6,636 6,644 1,459 1,562 1,624 1H 2023 1H 2024 1H 2025 1H 2023 1H 2024 1H 2025 R&D expense (RMBm) Net profit attributable to shareholders of the Company 1,2, 3（RMBm) R&D expense ratio（%） 4.3% 4.5% 4.7% 1,198 1,108 1,022 295 302 316 1H 2023 1H
Slide 17: Cash flow and Capex
Cash flow and Capex • Net operating cash flow and free cash flow were stable in 1H2025 • Stable cash flow performance as operating cash flow increased and capital expenditure stabilized; positive free cash flow for the seventh consecutive year since 2018 Cash flow and CAPEX (RMBm) 4,000 3,035 3,000
Slide 18: Increasing dividend payout
Increasing dividend payout The Company plans to maintain a dividend payout ratio1 at the level of 50% as of mid-2025; The cumulative dividends since listing have reached nearly RMB8.0bn, with a CAGR of over 20% Total dividend (RMBm) 984 757 766 645 585 544 455 395 404 397 420 442 349 335 268 279 220
Slide 19: Additional financial data
Additional financial data 1H2025 2024 Inventory turnover days1 126 days 139days Accounts receivable turnover Working capital 176 days 162days days1 Accounts payable turnover 91 days 107days days1 Bank balance & cash RMB8.95bn RMB 7.78bn Cash & liabilities Net cash RMB5.51bn RMB 4.19bn Net cash RMB3.
Slide 20: Disclaimer
Disclaimer This document does not constitute, or form part of any offer for subscription or sale of, or solicitation of any offer to subscribe for or sale of any securities of Shandong Weigao Group Medical Polymer Company Limited ("Weigao Group"), nor shall it be construed as calculated to invite an
Slide 21: 20
20
Shandong Weigao Group Medical Polymer Company — H1 2025 Earnings Presentation on 6ix